Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of CDX-0159 in chronic inducible urticaria
2021-006447-95Phase 2Active
- Sponsor
- Celldex Therapeutics
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic inducible urticaria (CIndU), Cold urticaria (CU), symptomatic dermatographism (SD) and 1 more comparing CDX-0159 dose-regimen arms with Placebo (2 arms). Primary endpoint: Proportion of patients with negative provocation test at Week 12 (ColdU cohort). Started Apr 2022; status: active.
02
Drugs
barzolvolimab
03
Conditions
chronic inducible urticaria (CIndU)Cold urticaria (CU)symptomatic dermatographism (SD)Dermatographia
Beyond the preview
Go deeper on 2021-006447-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006447-95.